CA2049342A1 - Formulations for stabilizing of igm antibodies - Google Patents

Formulations for stabilizing of igm antibodies

Info

Publication number
CA2049342A1
CA2049342A1 CA 2049342 CA2049342A CA2049342A1 CA 2049342 A1 CA2049342 A1 CA 2049342A1 CA 2049342 CA2049342 CA 2049342 CA 2049342 A CA2049342 A CA 2049342A CA 2049342 A1 CA2049342 A1 CA 2049342A1
Authority
CA
Canada
Prior art keywords
composition
igm
sodium
lyophilized
igm antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2049342
Other languages
English (en)
French (fr)
Inventor
Sally Bolmer
Jeffrey A. Mattis
Christopher P. Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2049342A1 publication Critical patent/CA2049342A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA 2049342 1989-03-27 1990-03-13 Formulations for stabilizing of igm antibodies Abandoned CA2049342A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32857989A 1989-03-27 1989-03-27
US328,579 1989-03-27

Publications (1)

Publication Number Publication Date
CA2049342A1 true CA2049342A1 (en) 1990-09-28

Family

ID=23281559

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2049342 Abandoned CA2049342A1 (en) 1989-03-27 1990-03-13 Formulations for stabilizing of igm antibodies

Country Status (4)

Country Link
EP (1) EP0465513A1 (ja)
JP (1) JPH04504253A (ja)
CA (1) CA2049342A1 (ja)
WO (1) WO1990011091A1 (ja)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05507924A (ja) * 1990-07-03 1993-11-11 アクゾ・エヌ・ヴエー 免疫反応性化合物
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
CA2097932A1 (en) * 1991-10-11 1993-04-12 Shojiro Yamazaki Antibody containing composition
ATE146359T1 (de) * 1992-01-21 1997-01-15 Stanford Res Inst Int Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
EP1428537B1 (en) * 2001-08-29 2008-11-19 Chugai Seiyaku Kabushiki Kaisha Stabilized preparations containing antibody
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
CA2976671C (en) 2010-03-01 2021-01-12 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
AU2011293554B9 (en) 2010-08-23 2015-03-19 Xbiotech Inc. Treatment for neoplastic diseases
HUE048876T2 (hu) 2011-05-09 2020-08-28 Mayo Found Medical Education & Res Rákos megbetegedések kezelése
CA2838964C (en) * 2011-07-05 2021-07-13 Novozymes Biopharma Dk A/S Albumin formulation and use
MX356808B (es) 2011-09-23 2018-06-14 Xbiotech Inc Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
EA201692502A1 (ru) 2014-06-16 2017-09-29 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Лечение миелом
SI3204413T1 (sl) * 2014-10-06 2020-07-31 Mayo Foundation For Medical Education And Research Sestave protiteles prenašalca ter metode za njihovo izdelavo in uporabo
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
JP6921802B2 (ja) * 2015-08-18 2021-08-18 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ キャリア結合剤組成物およびそれを作製および使用する方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3018340A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CA3035378A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
EP3510048A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Methods of treating pd-l1 expressing cancer
WO2018048958A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1546177A (en) * 1976-11-19 1979-05-16 Biokema Sa Process for the preparation of a stable injectable solution
JPS5822085B2 (ja) * 1977-07-19 1983-05-06 株式会社ミドリ十字 静注用ガンマ・グロブリン製剤
DE3875852T2 (de) * 1987-08-10 1993-03-18 Miles Inc Gereinigtes igm.

Also Published As

Publication number Publication date
EP0465513A1 (en) 1992-01-15
JPH04504253A (ja) 1992-07-30
WO1990011091A1 (en) 1990-10-04

Similar Documents

Publication Publication Date Title
CA2049342A1 (en) Formulations for stabilizing of igm antibodies
Sarciaux et al. Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying
EP0417193B1 (en) Freeze-dried formulation for antibody products
Kerwin et al. Effects of tween 80 and sucrose on acute short-term stability and long-term storage at− 20 C of a recombinant hemoglobin
AU695084B2 (en) Formulations for factor IX
US4496537A (en) Biologically stable alpha-interferon formulations
US9463241B2 (en) Method for stabilising an immunoglobulin G composition in liquid form
AU600246B2 (en) Stabilised human tissue plasminogen activator compositions
US20220257763A1 (en) Room temperature stable lyophilized protein
US20100056765A1 (en) Formulations That Inhibit Protein Aggregation
BR112012012080B1 (pt) Formulações de histidina-trealose do anticorpo t1h
EP0417191B1 (en) Formulation for antibody reagents
JPS6191131A (ja) 医薬品の吸着防止方法および組成物
US8372798B2 (en) High-concentration protein formulations and method of manufacture
KR20040018458A (ko) Ｃｅｔｕｘｉｍａｂ 및 폴리옥시에틸렌 소르비탄 지방산에스테르를 포함하는 액형 제제
AU676833B2 (en) Pharmaceutical compositions containing IL-6
JPH11502205A (ja) ｈＣＧ液体製剤
KR900004799B1 (ko) 안정한 감마 인터페론 제제 및 이의 제조방법
KR20200143449A (ko) 메글루민 염을 사용하여 단백질을 포함하는 제형을 안정화시키는 방법
JP2005508992A (ja) 凍結乾燥されたモノクローナル抗体組成物
JPH0137118B2 (ja)
RU2136313C1 (ru) Стабилизирующий состав для получения референс-сывороток, содержащих igm-антитела
WO2021141789A1 (en) Stable formulations of anti-cancer peptides
JPS6399022A (ja) 静脈内投与に適したガンマ・グロプリン
AU2002337895A1 (en) Lyophilized monoclonal antibody compositions

Legal Events

Date Code Title Description
FZDE Dead